| Application no. and date | 17753910.3 (espacenet) (Federated) (European Patent Register), 20170217 | | Patent/reg. no. and date | DK/EP 3416672, 20241023 | | Publication date | 20181226 | | Priority no. and date | US 201662296989 P, 20160218 | | EP pub. no. and date |
EP 3416672 20181226 | | Effective date | | | Applicant/owner | Melinta Therapeutics, LLC, 389 Interpace Parkway
Suite 450
Parsippany, NJ 07054, US | | Applicant ref. no. | | | Inventor | GRIFFITH, David, C., 8 Sylvan Way
Parsippany
NJ 07054, US,
FAR, Adel, Rafai, 8 Sylvan Way
Parsippany
NJ 07054, US,
LEHOUX, Dario, 8 Sylvan Way
Parsippany
NJ 07054, US,
KRISHNA, Gopal, 8 Sylvan Way
Parsippany
NJ 07054, US | | Representative | | | Opponent | | | IPC Class | A61K 38/14 (2006.01) , A61K 47/40 (2006.01) , A61P 31/04 (2006.01) | | Title | ORITAVANCIN FORMULATIONS | | Int. application no. | US2017018340 | | Int. publication no. | WO2017143169 | | Related patent (certificate) | | | Status | Enhedspatent registreret | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
